Experiment 569507

Details

PropertyValue
Pharmacology
OrganismSerenoa repens (ARECACEAE)
CitationCARILLA,E: BRILEY,M: FAURAN,F: SULTAN,C: DUVILLERS,C:. (1984). BINDING OF PERMIXON, A NEW TREATMENT FOR PROSTATIC BENIGN HYPERLASIA. TO THE CYTOSOLIC ANDROGEN RECEPTOR IN THE RAT PROSTATE.. 20(1)
Amount utilized
Compound isolated
DiseaseTHE BENIGN HYPERPLASIA OF THE PROSTATE IS A MANIFESTATION OF AGING, INVOLVING THE ACCUMULATION, WITHIN THE GLAND OF DIHYDROTESTOSTERONE, THE PROBABLE MEDIATOR OF THE HYPERPLASIA. BINDING STUDIES WERE PERORMED ON THE CYTOSOLIC ANDROGENIC RECEPTOR OF THE RAT PROSTATE USING [1H]METHYLTRIENOLONE AS A LIGAND. THE BINDING OF [1H]METHYLTRIENOLONE AT 5 NM, WAS INHIBITED BY VARIOUS DRUGS, SUCH AS METHYLTRIENOLONE AND CYPROTERONE ACETATE. PREMIXON, A LIPOSTEROLIC EXTRACT OF THE PLANT. SERENO REPENS B, INHIBITS COMPETITIVELY THE BINDING TO THE CYTOSOLIC RECEPTOR OF THE RAT PROSTATE. VARIOUS VEGETABLE AND MINERAL OIL, THE PLANT STEROID: BETA SITOSTEROL AND THE ANTIRPOSTATIC DRUG: TADENAN, WERE ALL FOUND TO BE INACTIVE. THE ANTIPROSTATIC ACTIVITY OF PREMIXON SHOWEN IN ANIMAL STUDIES AND CONTROLLED CLINICAL TRIALS, MAY THUS RESULT FROM A DIRECT ACTION AT THE CYTOSOLIC RECEPTOR.
Dose amount367.5 MCG
Number1
Qualitative resultACTIVE
AnimalRAT
Per unitML
Dose expressionIC50
ExtractHEXANE EXT
GenderMALE